Cancer Immunotherapy and CAR T Cells
DOI:
https://doi.org/10.55175/cdk.v45i12.683Kata Kunci:
Cancer, immune system, immunotherapyAbstrak
Within the past decade, radical changes of idea emerged from the works of research scientists, medical experts, and oncologists. Instead of treating cancers with man-made chemicals or chemotherapy and radiotherapy, or surgically remove the tumor, we should unleash the power of our own body immune system. Indeed, such approach has borne fruits and benefited at least for some cancer patients. This review describes various types of immunotherapy known to date, with its beneficial effects, albeit some with serious harmful effects. To understand how immunotherapies work, we also review some biologic characteristics of cancer cells that let them evade attacks from our immune system; cancer microenvironment that works in favor or protecting the growth of cancer against our immune system will also be discussed.
Hanya dalam jangka 10 tahun terakhir, telah terjadi perubahan radikal hasil penelitian para ahli, ahli medis, dan ahli onkologi. Di samping cara klasik penyembuhan kanker seperti obat-obat kimia sintetik atau kemoterapi dan radioterapi atau pembedahan, kini para ahli telah menggunakan sistem imunitas tubuh penderita sendiri. Cara ini telah terbukti dalam pengobatan beberapa pasien kanker. Dalam ulasan ini kami akan memaparkan beberapa immunoterapi saat ini dengan hasil baik meskipun masih terdapat beberapa efek samping berbahaya. Untuk memahami bagaimana imunoterapi bekerja, akan diulas dan dijelaskan sifat-sifat biologi sel kanker, dan bagaimana kanker sel bisa menghindari serangan sistem imun; dan lingkungan mikrokanker (cancer microenviroment) yang melindungi kanker dari sistem imun.
Unduhan
Referensi
Couzine-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342(6165):1432-3.
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271(5256):1734-6.
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cell with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advance leukemia. Sci Transl Med. 2011;3(95) 95ra73.
Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21:215-23.
Busch W. Aus der Sitzung der medicinschen section Vom 13 November 1867, Berlin Klin Wochenschr 1868;5:137
Fehleisin F. Ueber die Zuchlung der Erysipelkokken auf kunstlichen nahrboden und ihre ubertragbarkeit auf den Menschen. Dtsch Med Wochenschr 1882;8:553-4.
Coley WB. The treatment of sarcoma with the mixed toxin of erysipelas and Bacillus prodigiosus. Boston Med Surg J. 1908;158:175-82
Olds LJ, Clarke DA, Benacerraf B. Effects of Bacillus Calmette-Guerin infection on transplanted tumors in the mouse. Nature 1959;184:291-2
Morales A, Eidinger D, Bruce AW. Intracavity Bacillus Calmette-Guerin in the treatment of superficial bladder tumor. J Urol. 1976;116:180-3
Groopman JE, Gottlieb MS. Kaposi’s sarcoma: An oncologic looking glass. Nature 1982;299:103-4.
Hanahan D, Weinberg RA. Hall marks of cancer: The next generation. Cell 2011;144:646-70
Loeb LA. Human cancers express mutator phenotypes: Origin, consequences and targeting. Nat Rev Cancer 2011;11:450-7
Lindahl T, Wood RD. Quality control by DNA repair. Science 1999;286:1897-905.
Burnet FM. The concept of immunosurveillance. Proc Exp Tumor Res. 1970;13:1-27
Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody EMR8-5. Cancer Sc. 2006;97:1374-80
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive and acquired resistance to cancer immunotherapy cell 2017;168(4):707-23
Ibiayi DJ, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 2018;15:81-94
Miething C, Scuoppo C, Bosbach B, Appelmann I, Nakitandwe J, Ma J, et al. PTEN action in leukaemia dictated by the tissue microenvironment. Nature (2014);510:402-6
Hanahan D, Coussens LM. Accessory to the crime: Function of cells recruited to the tumor microenvironment. Cancer Cell 2012;(21):309-22
Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226:148-57
O’Connor T, Borsig L, Heikenwalder M. CCL2-CCR2 signaling in disease pathogenesis. Endocrine, Metabolic Immune Disorders Drug Targets 2015;15(2): 105-18.
Steinman RM, Cohen ZA. Identification of a novel cell type in peripheral lymphoid organs of mice, volume 1: Morphology, quantitation, tissue distribution. J Exp Med. 137(5):1142-62
Gardner TA, Elzey BD, Hahn NM. Sipuleucel-T (Ptovenge) autologous vaccine approved for treatment of man with asymptomatic or minimally symptomstic castrate-resistant metastasis prostate cancer. Human Vaccine Immunother. 2012;8:534-9
di Pietro A, Tosti G, Ferrucci PF, Testori A. Oncophage (Vitespen) – Heat shock protein-peptide complex 96-based vaccine in melanoma. How far we are, how far we can get? J Human Vaccines 2009;5(11):727-37
Ali OA, Emerich D, Dranoff G, Mooney DJ. In situ regulation of DC subsets and T cells mediates regression in mice. Sci Translat Med. 2009;1(8): 8-19
Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 02 April 2015. DOI: 10.1126/Science.aaa 3823.
Squadrito ML, Hansen SK, Cianciaruso C, De Palma M. EVIR: chimeric receptors that enhance dendritic cells cross-dressing with tumor antigens. Nat Methods 2018;15:183-6
Saguv-Barfi, et al. Deliver locally, act globally. Sci Translational Med. 2018;10 (426): eaan4488.
Sutlu T, Alici E. Natural killer cell based immunotherapy in cancer: Current insight and future prospect. J Int Med. 2009;266(2):154-81.
Raje N, Anderson KC. Thalidomide and immuno-modulatory drugs as cancer therapy. Cur Opin Oncol. 2002;4(6):635-40
Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am. 2012;26(3):447-81
Qi J, Li X, Peng H, Cook EM, Dadashian EL, Wiestner A, et al. Potent and selective antitumor activity of T cell-engaging bispecific antibody targeting a membraneproximal epitope of ROR-1. Proc Natl Acad Sci U S A. 2018;115(24):5467-76.
Nirschi CJ, Drake CG. Molecular pathways: Co-expression of immune. Immune checkpoint molecules, signaling pathway and implication for cancer immunotherapy. Clin Cancer Res. 2013;19:4917-24.
Rudd CE, Taylor A, Schneider H. CD28 and CTLA4 coreceptor expression and signal transduction. Immunol Rev. 2009;229:12-26
Kim ES, Kim JE, Patel MA, Mangraviti A, Ruzevick J, Lim M. Immune checkpoint modulators: An emerging antiglioma armamentum. J Immunol Res article # 104683607, 2015.
Pardoll DM. The blockade of immune check points in cancer immunotherapy. Mat Rev Cancer 2012;12:252-64
Pendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, et al. Indoleamine 2,3 deoxygenase pathway of pathogenic inflammation and immune escape in cancer. Cancer Immunol Imuunother. 2014; 63(7): 721-35
Yearly JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2 expression in human tumors: Relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23: 3158-67.
Chen DS, Mellman I. Oncology met immunology: The immunity cycle. Immunity 2013;39:1-10
Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulate CD8+ T cell accumulation and effector function in murine self- and tumor tolerance system. J Clin Invest. 2007;117:3383-92.
Morse MA. Technology evaluation: Ipilimumab. Medarex/Bristl-Myers Squibb. Curr Opin Mol Ther. 2005;7:588-97
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEJM 2010;363:711-23.
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;313:616-22.
Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumor activity of durvalumab plus tremelimumab in non small cell lung cancer in multicenter phase 1b study. Lancet Oncol. 2016;17:299-308
Infante JR, et al. Clinical pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. J Clin Oncol. 2013;31(suppl : abstr. 3044)
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD1 antibody in cancer. NEJM 2012; 366:2443-54.
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapyn in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomized, controlled, open label, phase III trial. Lancet Oncol. 2015;16:375-84.
Fehrerbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicenter open label, phase 2 randomized controlled trial. Lancet 2016;387:1837-46.
Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MED14736) an anti-programmed cell death ligand-1 immune checkpoint inhibitor in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;10:3119-25.
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. NEJM 1988; 319:1676-80
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptive transferred tumor reactive T cells. Nat Med. 2013;19:747-52
Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370-83
Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEJM 2011;365:725-33
Lim WA, June C. The principles of engineering immune cells to treat cancer. Cell 2017;168:724-38
Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejaction responses contribute to attenyated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in human. Biol Blood Marrow Transplant 2010;16:1245-56
Salvodo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves as persistence of chimeric antigen receptor modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822-6.
Carpetino C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells. PNAS USA 2009;106:3360-5.
Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Neurotoxocity due to CAR T cells. Nature Med [Internet] 2018. Available from : www.nature.com/articles/s41591-018-0036-4
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
